QNTM

Quantum BioPharma Ltd

1.61

Nov 13 • 3:59 PM ET -0.17 (-9.55%)

1.57

Aftermarket • 7:52 PM ET -0.04 (-2.32%)

Healthcare Biotechnology Canada Nano NASD

Nov 13, 7:40 AMQuantum BioPharma reported Q3 2026 results, with shareholders’ equity up 91% to US$9.77 million and cash plus digital assets totaling US$12.22 million.

Peers: IMUX CLNN TLSA AZR NGEN CMND PBM MSLE ATHE DRUG

| Held by: PSIL

Scroll to Statements

Index	-
Market Cap	13.02M
Enterprise Value	-0.51M
Income	-20.14M
Sales	0.00M
Book/sh	1.37
Cash/sh	1.54
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	7
IPO	Jun 08, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.17
P/C	1.05
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.72
Current Ratio	1.72
Debt/Eq	0.08
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-4.33
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-135.55% -24.71%
Sales past 3/5Y	- -
EPS Y/Y TTM	57.84%
Sales Y/Y TTM	-
EPS Q/Q	97.34%
Sales Q/Q	-
Earnings	Aug 13 AMC
EPS/Sales Surpr.	- -

Insider Own	13.05%
Insider Trans	0.00%
Inst Own	6.77%
Inst Trans	3.42%
ROA	-127.92%
ROE	-196.88%
ROIC	-170.60%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-26.73%
SMA50	-44.44%
SMA200	-56.26%
Trades

Shs Outstand	8.59M
Shs Float	7.03M
Short Float	6.26%
Short Ratio	2.50
Short Interest	0.44M
52W High	12.42 -87.04%
52W Low	1.71 -5.85%
Volatility	12.15% 8.19%
ATR (14)	0.20
RSI (14)	21.96
Beta	0.50
Rel Volume	0.50
Avg Volume	175.74K
Volume	87,559

Perf Week	-23.52%
Perf Month	-40.59%
Perf Quarter	-56.25%
Perf Half Y	-76.36%
Perf YTD	-77.95%
Perf Year	-79.06%
Perf 3Y	-97.62%
Perf 5Y	-98.40%
Perf 10Y	-
Recom	1.00
Target Price	8.00
Prev Close	1.78
Price	1.61
Change %	-9.55%

Consensus

Strong Buy

Avg. Price Target

$8.00

Implied Upside

+396.9%

Analysts1incl. previous ratings

Rating Distribution1 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 31, 2026	Initiated	RRodman & Renshaw	Buy	$8	+396.9%

Nov-13-26 07:05AM	Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up (GlobeNewswire) -9.55%
Nov-11-26 03:30PM	Quantum BioPharma (QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control (NewMediaWire)
07:07AM	Quantum BioPharma Announces Results of Annual General and Special Meeting of Shareholders and Closing of Private Placement of Class A Multiple Voting Shares (GlobeNewswire)
Nov-05-26 05:00PM	Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold (GlobeNewswire)
03:00PM	Quantum BioPharma (QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth (NewMediaWire)
03:30PM	Loading…
Nov-03-26 03:30PM	Quantum BioPharma (QNTM) Draws 'Men's Fitness' Spotlight as Unbuzzd Trial Shows Early Promise (NewMediaWire)
Oct-20-26 02:30PM	Quantum BioPharma (QNTM) Featured in Men's Fitness Article Examining Unbuzzd Clinical Trial Results (NewMediaWire)
Oct-08-26 08:00AM	World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares (GlobeNewswire)
Oct-07-26 03:30PM	Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial (NewMediaWire)
Oct-06-26 03:00PM	Quantum BioPharma (QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial (NewMediaWire) -5.50%
12:30PM	Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial (FinanceWire)
06:00AM	Quantum BioPharma Signs Contract with Thermo Fisher Scientific's Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis (GlobeNewswire)
Sep-25-26 03:00PM	Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing (NewMediaWire)
Sep-24-26 08:00AM	Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO (GlobeNewswire)
Sep-23-26 02:30PM	Quantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments (NewMediaWire)
08:00AM	Loading…
Sep-17-26 08:00AM	Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target (GlobeNewswire)
Sep-15-26 03:30PM	Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit (NewMediaWire)
08:00AM	Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto (GlobeNewswire)
Sep-11-26 08:30AM	Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials (GlobeNewswire)
Sep-09-26 08:30AM	Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment (GlobeNewswire) +8.81%
Sep-01-26 07:00PM	Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange (GlobeNewswire)
Aug-21-26 07:00PM	Quantum Biopharma Provides Corporate Update (GlobeNewswire) -5.81%
Aug-20-26 02:40PM	Quantum BioPharma (QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves (NewMediaWire)
Aug-17-26 02:43PM	Quantum BioPharma (QNTM) Reports Lower Q2 Expenses, Advances Lucid-MS Into Phase 2 (NewMediaWire)
Aug-14-26 07:00AM	Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial (GlobeNewswire) +17.65%
Aug-13-26 02:30PM	Quantum BioPharma (QNTM) Targets Disability Drivers Beyond Relapse Rates in Multiple Sclerosis (NewMediaWire) -7.18%
Aug-10-26 03:30PM	Quantum BioPharma (QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 (NewMediaWire)
07:00AM	Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis: (GlobeNewswire)
Aug-03-26 03:15PM	Quantum BioPharma (QNTM) Advances MS Imaging Study With Encouraging Preliminary Results (NewMediaWire) +5.54%
Jul-30-26 12:18AM	Quantum BioPharma Announces Closing of Debt Settlement (GlobeNewswire)
02:35PM	Loading…
Jul-28-26 02:35PM	Quantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans (NewMediaWire)
Jul-22-26 02:30PM	Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions (NewMediaWire) -5.63%
Jul-20-26 07:00PM	Quantum BioPharma Announces Intention to Settle Debt (GlobeNewswire) -6.17%
Jul-15-26 02:45PM	Quantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective Therapy (NewMediaWire)
Jul-10-26 02:30PM	Why Quantum BioPharma (QNTM) Is 'One to Watch' (NewMediaWire)
Jul-07-26 07:00PM	Quantum BioPharma Provides Corporate Update (GlobeNewswire)
Jul-01-26 03:00PM	Quantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast (NewMediaWire) -7.18%
Jun-29-26 03:30PM	Quantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging Study (NewMediaWire)
Jun-25-26 08:30AM	Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy (GlobeNewswire)
Jun-23-26 03:45PM	Quantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials (NewMediaWire) +5.19%
08:30AM	Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach (GlobeNewswire)
Jun-09-26 02:51PM	Quantum BioPharma (QNTM) Advances Proprietary Therapy for MS Treatment (NewMediaWire)
Jun-04-26 03:30PM	Quantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets (NewMediaWire) -8.20%
Jun-02-26 03:50PM	Quantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast (NewMediaWire)
07:40AM	Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns (GlobeNewswire)
Jun-01-26 07:30PM	Quantum BioPharma Provides Corporate Update (GlobeNewswire) -23.47%
May-19-26 02:05PM	Quantum BioPharma (QNTM) Reports Midpoint Enrollment Milestone in MS Imaging Study (NewMediaWire) +11.64%
May-18-26 10:37AM	Quantum BioPharma Shares Climb as Multiple Sclerosis Imaging Study Advances (QNTM) (InvestorsHub) -7.93%
03:00AM	Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital (GlobeNewswire)
May-07-26 07:00AM	Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026 (GlobeNewswire) -5.11%
Apr-27-26 07:45PM	Quantum BioPharma Provides Corporate Update (GlobeNewswire) +23.27% +20.67%
Apr-22-26 09:16AM	Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant (GlobeNewswire)
Apr-02-26 08:30AM	Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied (GlobeNewswire) -9.75%
Apr-01-26 08:02AM	Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis (GlobeNewswire) -8.70%
Mar-30-26 07:50AM	Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis (GlobeNewswire) -10.27%
Mar-27-26 07:30PM	Quantum Biopharma Provides Corporate Update (GlobeNewswire) +24.54%
08:10AM	Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status (GlobeNewswire)
Mar-26-26 08:00AM	Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis (GlobeNewswire) -11.95%
Mar-23-26 08:24AM	Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd (GlobeNewswire) +38.39%
Mar-20-26 07:35PM	Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering (GlobeNewswire) -5.08%
Mar-11-26 07:55PM	Quantum BioPharma Provides Corporate Update (GlobeNewswire) -25.00% +21.90%
Mar-10-26 07:45PM	Quantum BioPharma Provides Corporate Update (GlobeNewswire) -16.67%
Dec-23-25 08:00AM	Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) (GlobeNewswire) -11.51%
Dec-22-25 07:00AM	World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares (GlobeNewswire) +20.25%
Dec-19-25 04:52PM	World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares (GlobeNewswire)
Dec-10-25 08:00PM	Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update (Newsfile) -7.26%
Dec-01-25 07:00AM	Investigative News Program W5 Airs Final Segment on USD $700 Million Stock Market Manipulation Lawsuit of Quantum Biopharma Involving CIBC and RBC (GlobeNewswire) -11.65%
Nov-28-25 09:30AM	REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC (GlobeNewswire) -14.99%
Nov-27-25 04:00PM	Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC (GlobeNewswire)
Nov-26-25 09:30AM	Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5 (GlobeNewswire) +41.92%
Nov-25-25 04:00PM	Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5 (GlobeNewswire) +29.68%
Nov-07-25 07:00AM	Quantum Biopharma Reports Strong Third Quarter Results Maintaining 'No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio (GlobeNewswire)
Oct-31-25 07:51PM	Quantum BioPharma Ltd. Provides Corporate Update (GlobeNewswire) -11.72%
Oct-29-25 09:00PM	Quantum BioPharma Ltd. Announces Corporate Updates (Newsfile)
Oct-23-25 08:15AM	Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication (GlobeNewswire) +6.02%
Oct-20-25 08:30AM	Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend (GlobeNewswire)
Oct-14-25 08:15AM	Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group (GlobeNewswire) +5.27%
Oct-08-25 08:00AM	Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock (GlobeNewswire) -8.21%
Oct-07-25 11:00AM	Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View (ACCESSWIRE)
Oct-03-25 07:00AM	Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case (GlobeNewswire)
Oct-02-25 07:57AM	Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial (GlobeNewswire) +9.50%
Oct-01-25 07:50AM	Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials (GlobeNewswire)
Sep-29-25 07:40AM	Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders (GlobeNewswire)
Sep-26-25 08:00PM	Quantum BioPharma Announces Corporate Updates (Newsfile)
Sep-24-25 08:30AM	Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025 (GlobeNewswire) -6.70%
Sep-18-25 08:10AM	Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance (GlobeNewswire) +12.49%
Sep-12-25 07:50AM	Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT (GlobeNewswire) +7.55%
Sep-10-25 07:00AM	Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target (GlobeNewswire) +27.42%
Aug-21-25 07:00AM	Quantum BioPharma Announces Corporate Updates (GlobeNewswire)
Aug-11-25 06:32PM	Quantum BioPharma Announces Update to Previously Announced Private Placement (Newsfile) -10.10% -7.35%
07:40AM	Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial (GlobeNewswire)
Aug-08-25 08:00AM	Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients (GlobeNewswire) +12.30%
Aug-07-25 07:00AM	Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt (GlobeNewswire)
Aug-05-25 07:34AM	Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS) (GlobeNewswire) -11.62%
Aug-04-25 07:33AM	Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing (GlobeNewswire) +17.30%
Jul-31-25 07:24AM	Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO (GlobeNewswire)
Jul-22-25 07:00AM	Quantum BioPharma Makes Strategic Investment in GameStop Corp. (GlobeNewswire) -7.80%
Jul-08-25 08:00AM	Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom (GlobeNewswire) +5.13%
Jun-27-25 04:30PM	Quantum BioPharma Announces Private Placement (GlobeNewswire) -6.77%
04:30PM	Quantum BioPharma Announces Private Placement of 12 Class A Multiple Voting Shares at a Price of $50 Per Share (GlobeNewswire)

Show Previous News

Quantum BioPharma Ltd. is a biopharmaceutical company, which engages in building a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. It operates through the Biopharmaceutical and Strategic Investments segments. The Biopharmaceutical segment focuses on furthering the research and development of the drug candidates and the development of a treatment for alcohol misuse for application in hospitals and other medical practices. The Strategic Investments segment is involved in the generation of returns and cash flow through the issuance of loans secured by residential property, with FSD Strategic Investments having a first or second collateral mortgage on the secured property. The company was founded by Thomas Fairfull, Zeeshan Saeed, and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

Co-FounderMr. Zeeshan Saeed

Co-Founder & Executive Non-Independent Co-ChairmanMr. Anthony John Durkacz

CPAMr. Donal Carroll C.M.A.

Ph.D.Dr. Andrzej Chruscinski M.D.

ControllerMr. Nathan Coyle CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

QNTM

Quantum BioPharma Ltd

Upgrade your Finviz experience

All the Features.
Half the Price.